Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Markedly increased MMSET expression was found in 1 MM showing associated FGFR3 and MMSET signals on an unidentified chromosome.
|
15543617 |
2005 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Nearly half of these tumors are nonhyperdiploid and mostly have immunoglobulin H (IgH) translocations that involve 5 recurrent chromosomal loci, including 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (fibroblast growth factor receptor 3 [FGFR3] and multiple myeloma SET domain [MMSET]), 16q23 (c-maf), and 20q11 (mafB).
|
15090448 |
2004 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the myeloma-associated oncogene FGFR3, which upregulates bcl-x(L), delayed but did not prevent caspase-3-mediated killing.
|
12907145 |
2003 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
From a clinical standpoint, it is critical to identify MM patients carrying the t(4;14) translocation, which is present in 15% of myelomas and is associated with dysregulation of WHSC1/MMSET and often FGFR3.
|
22160056 |
2011 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
|
12433679 |
2003 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic FGFR3 mutations have been identified in several cancer entities such as urothelial carcinoma and multiple myeloma.
|
17172848 |
2006 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
|
22329352 |
2012 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The identification of these overlapping sets of co-modulated tyrosine phosphorylations presents an outline of an FGFR3 network in the MM model and demonstrates the potential for pharmacodynamic monitoring by label-free quantitative phospho-proteomics.
|
19901323 |
2009 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074.
|
14715624 |
2004 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Translocation t(4;14) is observed in about 15% of patients with MM leading to constitutive activation of FGFR3 in two-thirds of these patients.
|
30349651 |
2018 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma.
|
11466624 |
2001 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
To detect FGFR3 protein expression, bone marrow (BM) aspirate from 200 consecutive newly diagnosed (n = 116) or relapsing (n = 74) MM patients was studied by flow cytometry (FC) using anti-CD138 and anti-FGFR3 antibodies.
|
17223917 |
2007 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Expression of fibroblast growth factor receptor 3 (FGFR3), presumptively dysregulated on der(14), was detected by RT-PCR in only 23 of 31 (74%) patients with t(4;14)(+) MM.
|
12393535 |
2003 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Findings from multiple myeloma (MM) indicate that FGFR3 also can act as an oncogene, and mutation of codon 249 in the fibroblast growth factor receptor 3 (FGFR3) gene was recently detected in 3/12 primary cervical carcinomas.
|
11904459 |
2001 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that FGFR3 mutations occur in only a small fraction of MM cases with t(4;14).
|
11529856 |
2001 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
New information regarding FGFR3 as an oncogene as well as how activating mutations may contribute to disease evolution and may be an important target for novel therapeutics of MM is presented.
|
11722983 |
2001 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Frequent FGFR3 kinase activating mutations in MM with t(4;14) translocations substantiate an oncogenic role for FGFR3.
|
9787135 |
1998 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
|
19147757 |
2009 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutation of Lys650-->Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas.
|
10918587 |
2000 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among recurrent IGH translocations in MM, the frequency of t(4;14) (IGH and FGFR3) or t(11;14) (IGH and CCND1) is greater than the frequency of t(14;16) (IGH and MAF).
|
23460268 |
2013 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR3 is thus a plausible candidate for targeted therapy in a subset of MM patients.
|
15029211 |
2004 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
As a part of these translational efforts, novel drugs that inhibit oncogenic proteins overexpressed in defined molecular subgroups of the disease, such as FGFR3 and MMSET in t(4;14) MM, are currently being developed.
|
23233602 |
2012 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in multiple myeloma and peripheral T-cell lymphoma.
|
23696246 |
2014 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
|
27509849 |
2016 |